|
業務類別
|
Biotechnology |
|
業務概覽
|
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA). |
| 公司地址
| 131 Dartmouth Street, 3rd Floor, Boston, MA, USA, 02116 |
| 電話號碼
| +1 650 503-9095 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.adicetbio.com |
| 員工數量
| 102 |
| Mr. Chen Schor, M.B.A. |
Director, Chief Executive Officer and President |
美元 627.59K |
12/03/2026 |
| Dr. Donald Healey, PhD |
Chief Technology Officer |
-- |
29/04/2025 |
| Mr. Nick Harvey |
Chief Financial Officer and Principal Accounting Officer |
美元 461.69K |
12/03/2026 |
| Dr. Blake Aftab, PhD |
Chief Scientific Officer |
美元 470.69K |
29/04/2025 |
| Dr. Julia D. Maltzman, M.D. |
Chief Medical Officer |
-- |
29/04/2025 |
|
|
| Dr. Lloyd Klickstein, M.D.,PhD |
Independent Director |
12/03/2026 |
| Mr. Chen Schor, M.B.A. |
Director, Chief Executive Officer and President |
12/03/2026 |
| Mr. Steve Dubin, J.D. |
Independent Director |
12/03/2026 |
| Mr. Michael Grissinger |
Independent Director |
12/03/2026 |
| Dr. Jeffrey A. Chodakewitz, M.D. |
Independent Director |
12/03/2026 |
| Ms. Katie Peng |
Independent Director |
12/03/2026 |
| Dr. Andrew Sinclair, PhD |
Independent Director |
12/03/2026 |
|
|
|
|
